Figure 3.

Intratumoral ICOS Agonistic (Apt8a) Treatment in Combination with CTLA-4 Blockade Promotes Antitumor Immune Response

(A) B16/F10 melanoma tumor-bearing mice were treated with ICOS Apt8a intratumorally as well as anti-CTLA-4 antibody intraperitoneally on days 4, 7, and 10, and splenocytes were extracted at day 14 and then cocultured with B16/F10 irradiated cells. As measurement of T cell activation, proliferation was assessed by ³H incorporation (B) and IFN-γ production by ELISPOT (C) and ELISA (D). (Data are expressed as the mean ± SEM of three mice per group. Experiments were repeated twice with similar results.) *p < 0.05, ***p < 0.005.